INVESTMENT HISTORY
Arrow successfully attracted over £40 million investment from a broad group of high-quality international venture capital investors since its foundation in 1998.
Financing History
| Date of Financing | Type | Participants | Amount Raised |
| 1998 | Seed | Unibio & founding scientists | £1.5 million |
| 1999 | Private Shareholder | Unibio & private shareholders | |
| 2000 | Series A | GIMV (lead), Alta Partners, 3i Group, TVM Capital, NVM and Unibio | £11.1 million |
| 2002 | Series A | GIMV (lead), Alta Partners, 3i Group, TVM Capital, NVM and Unibio | £7 million |
| 2004 | Series B | Atlas Venture (lead), Alta Partners, 3i Group, GIMV, ITX, Merlin BioMed Group, NIF, NVM, Scottish Widows Investment Partnership, TVM Capital and Unibio | £23.3 million |
| 2007 | Acquisition | AstraZeneca | $150 million |
| site by uc4 | site map | legal | privacy |